Policy & Regulation
Ministry of Health and Welfare, MFDS to hold KONECT clinical trials conference starting on the 13th Virtual control groups can reduce patient enrollment by 30% to 50%; regulatory alignment takes center stage

In drug development, artificial intelligence (AI) and digital twin technology have emerged as key clinical trial design methods that can influence regulatory approval, moving beyond their role as tools for identifying drug candidates.
The Ministry of Health and Welfare said on the 12th that it will hold the 2026 KONECT International Conference on Clinical Trials for three days, from the 13th to the 15th, at The Grand Lotte Seoul. The event, hosted by the ministry and the Ministry of Food and Drug Safety (MFDS) and organized by the Korea National Enterprise for Clinical Trials, will bring together about 1,500 people from domestic and international pharmaceutical and biotech companies, research organizations and global regulatory agencies, including the U.S. Food and Drug Administration (FDA).
Participants will focus on AI-based clinical trial design and data use. The program will begin with a keynote address on the global commercialization of Korea's lung cancer drug Leclaza, followed by a look at Eli Lilly's next-generation clinical strategy for metabolic diseases and real-world applications of data by global AI companies, including Unlearn.ai and Generate:Biomedicines.
In traditional drug development, assigning large numbers of patients to placebo control groups in Phase 3 trials has posed ethical and practical obstacles. In the development of treatments for rare and intractable diseases or severe cancers, patients assigned to placebo groups have often dropped out, and difficulties recruiting participants have frequently led to trials being discontinued.
Digital twin-based virtual control groups are created by training machine-learning models on historical clinical trial data and electronic medical records (EMRs) to generate digital control-group replicas with disease progression trajectories matching those of real patients. The approach is drawing attention as an alternative that can reduce enrollment in real-patient control groups by 30% to 50% while maintaining statistical validity.
At the conference, regulatory alignment between the FDA and MFDS will be a major topic, going beyond a simple introduction to the technology. Companies' efforts to reduce costs could be undermined if synthetic control data generated by AI algorithms fail to meet regulators' conservative standards for evaluating safety and efficacy.
The FDA is refining its standards for assessing the reliability and bias of external control data as it issues increasingly detailed guidance on real-world evidence (RWE) and AI-based clinical modeling. The MFDS is also moving quickly to align with global standards as it updates guidance on early-phase cancer trials and AI-based regulatory innovation.
For domestic biotech ventures seeking global licensing deals and overseas expansion, these changes in clinical trial design are directly tied to survival. When considering technology licensing, multinational pharmaceutical companies scrutinize whether clinical trial data have precise statistical evidence that meets the requirements for expedited review or accelerated approval in the United States and Europe.
However, algorithmic bias and the black-box nature of data remain challenges to be addressed. Differences in EMR formats across medical institutions, as well as racial and regional differences, could introduce bias into virtual control-group data and increase the risk of rejection during regulatory review. Standardization efforts to demonstrate data transparency and algorithm reproducibility to regulators are expected to be a turning point that will determine the future success of biotech ecosystems in Korea and abroad.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
The ‘Valley of Death’ for Infectious Disease Treatments: Cross-Agency Coordination Is Key

Mounjaro Costs 59,000 Won in Japan, 300,000 Won in Korea, Sparking Price Debate

SME Ministry aims to develop 20 AI startups valued at 1 trillion won by 2030

MFDS to Commission Domestic Production of 3 Essential Cancer and Antibiotic Drugs, Supply Expected This Year

Up to 6 Bottles of Obesity Drugs Purchased Abroad Allowed Into Korea Starting Tomorrow

‘Public Health Care AI Highway’ Opens, Cutting Referral Form Drafting From 10 Minutes to 1